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1. Introduction 
In healthy human hearts, only 10-20% of the total cells are contractile cardiomyocytes and, at 
the age of 25 years, no more than 1% of them are annually substituted by progenitor cells, 
this percentage reducing to less than 0.5% at the age of 75. In total, less than 50% of 
cardiomyocytes are renewed during a normal human life span [1]. For this reason, the topic 
of cardiac repair is among the major challenges for the tissue engineers worldwide. In fact, 
cardiac diseases are a predominant cause of mortality and morbidity in industrialized 
countries, despite the recent advancements achieved in pharmacological treatment and 
interventional cardiology procedures. Nonetheless, end-stage heart failure management still 
relies on organ transplantation as unique approach, and, notwithstanding the use of massive 
immunosuppressive drugs, still a percentage falling within 20%-40% of patients encounters 
immune rejection during the first year post-transplant [2]. Among the patients not facing 
severe immune rejection, almost 70% is forced to retire or reduce their working activity, 
their survival rate falling below 70% during the first five years post organ transplantation 
[3]. Last, but not least, the economic impact of cardiovascular diseases and stroke has been 
estimated in 2010 at $503.2 billion [4]. 
Currently, post-infarction myocardial revascularization protocols include the administration 
of raw bone marrow stem cells, while a number of clinical trials have been performed or are 
currently in progress in which different cell subsets are implanted in the damaged tissue by 
means of surgical techniques. The results of such trials are still controversial. In fact, when 
autologous skeletal myoblasts were injected into the heart of patients suffering from 
ischemic cardiomyopathy, the modest functional improvement obtained was impaired by 
the arising of arrhythmia events, thus requiring the adoption of a pacemaker [5]. On the 
other side, intracoronary administration of bone marrow mesenchymal stem cells resulted 
in minimal improvements in cardiac contractile function in patients with dilated 
cardiomyopathy [6]. These mild results were mostly ascribed to a paracrine effect exerted on 
host tissue, rather than to a direct contribution of stem cells to the contractile activity. 
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Thus, among the criticisms to be challenged before efficient cell therapy protocols for 
cardiac diseases can be setup, the choice of the appropriate cell subset to generate new 
vessels and contractile cardiomyocytes, as well as the route of cell delivery remain key steps. 
The solution of such problems requires additional efforts in basic research to clarify the 
processes leading to stem cell differentiation as well as technological advancements to setup 
efficient protocols to implant the cells.  
In principle, adult stem cells could be extracted from patient’s own tissues and expanded in 
culture by means of well-known techniques (Figure 1).  
 
 
Fig. 1. Cardiac Tissue Engineering paradigm. Adult stem cells can be harvested, purified 
from the patient and expanded in culture. Such cells can be delivered to the injured heart by 
injection (intramural or through bloodstream with or without injectable carriers), or in the 
form of solid bio-constructs. Stem cell-derived bio-constructs can be obtained by culturing 
the cells on scaffolds or by scaffold-free technology 
Nonetheless, a number of issues should be challenged before safe procedures to 
manipulate stem cells in vitro for cardiac transplant can be setup. In fact, stem cells should 
be amplified in vitro to reach a critical number (Figure 1). During this passage, malignant 
transformation is likely to occur in ex vivo cells when standard culture conditions are 
adopted to expand stem cells [7, 8]. On the other side, stem cells could encounter 
senescence after a short number of passages in vitro [9]. Moreover, the use of animal-
derived supplements during the phase of cell expansion would hinder the use of stem 
cells for cardiac cell therapy. 
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The employment of autologous stem cells would avoid the problem of immune rejection 
and the need for immune-suppressive drugs, while, in the treatment of pathologies for 
which a genetic basis is suspected the use of autologous cells is hampered. As far as the use 
of autologous cells is concerned, the possibility that a significant patient-to-patient 
variability in stem cell quality exists should be taken into account [10]. Finally, the use of 
cellular and tissue-based products in human disease therapy is subjected to regulations 
issued by the European Union and Food and Drug Administration (FDA) aimed at 
establishing classification criteria for advanced therapy medicinal products (ATMP). In 
particular, the European Regulation states that human cells to be used in cell therapy have 
to comply with the principles of Good Manufacturing Practice (GMP) protocols [11, 12]. 
2. Adult stem cells for cardiac repair 
A number of stem cells and progenitors have been so far proposed for cardiac repair, due to 
the inability of cardiomyocytes to proliferate after birth [1]. Among the cell sources 
challenged for the possibility to produce new cardiomyocytes, skeletal myoblasts have 
proven to be able to acquire a contractile phenotype in vitro [13]. Moreover, when implanted 
in vivo in a canine model of dilated cardiomyopathy (DCM), they attenuated cardiac 
remodeling [14]. This result is likely to be due to the fusion of skeletal myoblasts with the 
surrounding myocardium rather than to direct cell differentiation, as suggested by in vitro 
experiments [15]. As discussed in the following section, clinical trials demonstrated that 
skeletal myoblasts are not able to couple electrically with host tissue, leading to arrhythmia 
events [5].  
The role of hematopoietic stem cells (HSC) in cardiac repair has been investigated by several 
research groups and their contribution to cardiac regeneration in vivo has been heavily 
debated, being the ability of HSC to transdifferentiate to other lineages still questionable. 
Indeed, evidence of the ability of bone marrow-derived c-kit+ HSC to help cardiac tissue 
healing has been given using two different approaches: c-kit+ cells were (i) either delivered 
to the infarcted site by intramural injection [16] or (ii) mobilized from bone marrow through 
growth factor administration [17]. More recently, elegant experiments compellingly clarified 
that HSC are not able to acquire contractile phenotype in vivo [18-20]. Nonetheless, a subset 
of bone marrow hematopoietic precursors expressing CD34 and CD133 has been proven to 
contain endothelial progenitors. Thus, they have been tested for revascularization protocols 
in hind limb ischemic animals and could be proposed for cardiac infarction therapy [21]. On 
the other hand, the results obtained in preliminary investigations in which another bone 
marrow-derived stem cell subset, mesenchymal stem cells (BM-MSC or MSC) were 
challenged as a candidate for cellular cardiomyoplasty, raised great enthusiasm for such a 
cell subpopulation. Recent studies clarified that the direct contribution of MSC to cardiac 
repair in terms of production of new contractile cells is minimal if any, while a paracrine 
effect on the diseased tissue of such cells is universally recognized [22]. Such cells are also 
appealing for their ability to induce a certain degree of immune tolerance [23].   
The presence of a small reservoir of cardiac resident progenitor cells (CPC or CSC) has been 
recently demonstrated in human as well as in other mammals’ heart [24]. Such tissue-
resident cells participate in myocardial homeostasis and retain a limited regenerative 
capacity throughout organism lifespan [1]. All the subsets so far identified through the 
expression of stemness markers (c-kit+, Sca-1+, Islet-1+) demonstrated the ability to give 
birth to new contractile cells in vitro, while only c-kit+, Sca-1+ progenitors were shown to be 
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involved in post-natal cardiac tissue homeostasis in vivo [25]. In fact, the presence of Islet-1+ 
cells appears to be limited to fetal life and their contribution to the endogenous program of 
cardiovascular repair is still unknown; on the other hand, the very low number of c-kit+ and 
Sca-1+ cells in the myocardium is considered the limiting factor of cardiac regeneration [26]. 
Furthermore, among the adult stem cells, a novel “artificial” subset can be recognized: 
induced pluripotent stem cells (iPSC, Figure 2). This cell type can be produced in vitro by 
transducing somatic cells with a combination of transcription factors able to induce the 
nuclear reprogramming of differentiated cells. These cells, which display the functional 
features of pluripotent embryonic stem cells, have been credited of the ability to produce 
new cardiomyocytes. They could thus be the source of autologous, although genetically 
modified, patient-specific contractile cells [27]. Moreover, the possibility to directly obtain 
functional cardiomyocytes by the genetic reprogramming of postnatal cardiac or dermal 
fibroblasts has been demonstrated [28]. Such a result was firstly obtained in vitro but also 
when the cells were transplanted into mouse hearts one day after transduction of 
transcription factors (GATA-4, MEF-2c, Tbx-5) known to be involved in cardiac muscle 
development. Nonetheless, the reprogramming and differentiation efficiency of these cells 
appears to be really low, thus requiring an efficient purification step before they can be 
implanted in vivo. Additionally, safety concerns due to the use of genetically modified cells 
and / or viral vectors remain.  
 
 
Fig. 2. Induced Pluripotent Stem Cell Generation. Induced pluripotent Stem Cells (iPSC) can 
be generated by reprogramming somatic cells through their transduction with four 
transcription factors. iPSC share functional similarities with Embryonic Stem Cells (ESC) 
and can be differentiated towards cardiomyocytes, thus representing an autologous source 
of contractile cells 
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3. Stem cell delivery to the injured heart 
As previously said, cell route of delivery to damaged heart represents the major topic in 
the setup of efficient, minimally invasive techniques to treat cardiac pathologies. 
Recently, a number of techniques to deliver stem cells to the injured site have been 
proposed but questions remain regarding the optimal approach able to favor high cell 
retention, differentiation rate and clinically relevant improvement in cardiac 
performance. 
a) Direct injection 
Stem cell direct intramural injection, including trans-epicardial and trans-endocardial cell 
injection, is the elective strategy for patients with severe occlusion of coronary vessels. In 
particular, trans-epicardial approach consists in the direct injection of a high number of cells 
into the infarcted area or around the border zone. Endocardial stem cell injection is 
performed using catheters such as MyoStarTM injection catheter (Biosense Webster) 
integrated with imaging systems like NOGA® system (Cordis Corp., Warren, NJ, USA), 
which allows real-time three-dimensional reconstruction of left ventricle as well as the 
targeting and functional assessment of specific myocardial area [29]. Such procedures are 
highly invasive since they require open-heart surgery and gave contrasting results so far. 
For example, pre-clinical studies performed on experimental animals demonstrated that, 
although a certain extent of cardiac repair was achieved when bone marrow Stro-3+ 
perivascular cells are implanted in vivo, the cells vanished from the application site within 
few days [30]. In other reports, when Sca-1+ cardiac resident stem cells were injected in 
infarction border zone, a modest but significant improvement in cardiac function was 
reported, with evidence of cell engraftment and differentiation [31]. Finally, in another 
pre-clinical study, bone marrow-derived c-kit+ cells were shown to repair entire 
ventricular areas while massively engrafting and differentiating in contractile and 
vascular figures in vivo [32]. Of interest, independent groups already demonstrated that c-
kit+ bone marrow-derived hematopoietic stem cells fail to acquire contractile phenotype 
when implanted in diseased myocardium [19, 20]. Such discrepancies are not surprising 
since different stem cell subsets or preparation protocols were probably used in these 
studies.  
Stem cells can be delivered intravenously to the heart, through coronary arteries or even 
through retrograde coronary sinus. The major drawback of stem cells being infused through 
peripheral venous system seems to be the low retention of cells into infarcted area. Results 
obtained in pre-clinical animal models showed that this minimally invasive approach results 
in a significant percentage of injected cells being sequestered in lungs, liver or spleen, due to 
blood flow [33]. On the other hand, intracoronary or retrograde coronary sinus infusion of 
the cells are mainly performed after acute myocardial infarction using an angioplasty 
balloon and high pressure to deliver cells to heart muscle [34]. The coronary route was 
proven to be free of stem cell systemic delivery, while a limited number of cells could be 
found in the infarcted area [35].  
Finally, an interesting attempt with stem cells being injected into the pericardial cavity has 
been proposed. By this means, a higher number of cells could be deposited and retained 
in the pericardial cavity, while migration across the visceral pericardium is required 
(Table 1).  
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Table 1. Advantages and disadvantages of injecting stem cells by intravenous, 
intracoronary, intramyocardial, retrograde coronary sinus or intra-pericardial route 
b) Injectable scaffolds  
Injectable scaffolds are defined as materials offering the unique solution of replacing 
damaged myocardial ECM and/or delivering cells directly to the infarcted region while 
holding the potential for minimally invasive delivery [36]. Such scaffolds can be composed 
of biocompatible microspheres or in situ gelling materials having reasonable dimensions as 
to surpass capillary barrier. They are considered a promising tool for stem cell delivery to 
damaged myocardium. In situ gelling materials are generally made of components of 
extracellular matrix (ECM), which are induced to a transition after being implanted in situ. 
Complex injectable gelling materials have been prepared by decellularization technique out 
of ventricular or epicardial ECM, thus possibly avoiding animal-derived components and 
paving the way to the definition of patient-specific treatments.  
The use of injectable, synthetic microspheres has already been proven promising in the 
treatment of neurological diseases in vivo [37]. Recently the possibility of using injectable 
scaffolds in cardiac cell therapy has been explored by interfacing murine mesenchymal 
(mMSC) and cardiac stem cell (mCSC) lines with poly-lactic acid (PLA) microspheres 
having a diameter of 30 and 100 µm. Preliminary in vitro experiments demonstrated that 
such cells can be grown onto PLA microspheres while preserving their phenotype, but the 
formation of cell clumps can hamper the application of this technique [38]. The use of 
dynamic seeding techniques (i.e. bioreactors) would favor a more homogeneous distribution 
of the cells. An interesting approach has been recently proposed to deliver human 
mesenchymal stem cells to the injured myocardium: RGD-modified alginate microsphere 
(diameter: 200-700 µm) encapsulation of hMSC was setup. In vitro experiments showed that 
hMSC could survive, proliferate and migrate through the porous material. When 
intramyocardially injected in a rat model of myocardial infarction by left anterior 
descendant coronary (LAD) ligation, cell-loaded alginate microspheres promoted 
angiogenesis and prevented LV negative remodeling [39]. Nonetheless, few human cells 
were found in the injection area after few days, while microbead remains were still present 
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within host myocardium 10 weeks after the injection. The aspect of microbead resorption 
should thus be addressed before clinical perspectives could be foreseen. 
c) Scaffold-based technology 
The possibility of using biocompatible scaffolds to deliver stem cells to the injured heart has 
been explored by a number of independent research groups so far. The scaffolds proposed 
are natural of synthetic but when designing cardiac-specific constructs, a number of 
requirements should be fulfilled. For example, it cannot be neglected that myocardial 
contractile function relies on the transmission of electrical and mechanical forces throughout 
a functional syncytium. So, the integrity of the tissue has to be preserved. For this reason, a 
cardiac-specific scaffold should comply with tissue architecture and thus be deformable 
enough to indulge and, if possible sustain cardiac contraction. Moreover, as far as stem cell 
engraftment is concerned, scaffolds should be able to start at least cell alignment and 
commitment to favor stem cell electromechanical coupling with host tissue. In this respect, 
the work of Mandoli and collaborators using Cerium Oxyde nanoparticles to affect poly-
lactic acid film surface and obtain a controlled nanorugosity appears intriguing [40]. In fact, 
far from being a noxious compound for stem cells, ceria was able to induce cardiac stem cell 
alignment and growth. Nonetheless, cardiac tissue is extremely complex and highly 
demanding in terms of blood supply and catabolite removal, so that porous scaffolds that 
could allow microvascular branches formation and oxygen perfusion are to be preferred. To 
fulfill such requirements, the first attempts were performed by the group of Thomas 
Eschenhagen. Neonatal cardiomyocytes were seeded in Collagen I + Matrigel to produce 
Engineered Heart Tissue (EHT). Continuous contractile activity up to 1 week in vitro as well 
as cell survival and integration in vivo in singenic rat hearts were reported [41]. In another 
attempt, anisotropic accordion-like honeycomb scaffolds were prepared by excimer laser 
microablation using poly(glycerol sebacate) as an elastomeric tool to mimic anisotropic 
cardiac muscle stiffness distribution [42]. Although the authors demonstrated that such 
scaffolds promote neonatal rat cardiomyocyte alignment and contraction, in vivo testing has 
not been performed so far. The same material has been utilized to produce elastomeric 
patches on which human embryonic stem cell-derived cardiomyocytes were grown, 
showing that it is indeed possible to observe spontaneous beating activity in vitro up to 3 
months [43]. Such patches were shown to be suitable as delivery systems and, when sutured 
in the absence of cells onto healthy rat left ventricle, they did not affect cardiac contractile 
activity. More basic studies were also conducted to study the ability of stem cells to interface 
with different synthetic and natural materials. In this respect, few research groups focused 
on the possibility to drive a certain extent of stem cell commitment through tailoring 
scaffold physical and chemical properties, independently of biological cues. In this respect, a 
common agreement on the ability of stem cells to sense substrate rugosity and elasticity has 
been reached [44]. Thus, in order to rule out the occurrence of spontaneous events of 
differentiation in implanted cells, the possibility to induce in vitro stem cell commitment on 
scaffolds towards a desired phenotype is being investigated. Indeed, Engler and 
collaborators compellingly demonstrated that the possibility to affect stem cell fate 
determination by simply tuning substrate elasticity as to match tissue-specific stiffness, 
exists. Recently, this concept has been corroborated by other research groups, showing that 
cardiac resident progenitors (Sca-1+ CPC) can be committed to cardiac phenotype by the 
physico-chemical signals arising from matrix, but biological factors are needed to complete 
the differentiation process [45, 46]. 
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d) Preparation of thick cardiac substitutes by Scaffold-free technology  
To overcome the problem of poor cell retention reported in cell injection experiments in the 
heart [30] and avoid the release of possibly harmful scaffold byproducts, scaffold-free 
technology has been developed, in which cells are grown in a monolayer onto thermo-
responsive surfaces and easily detached in the form of cell sheet by lowering the 
temperature [47]. Such technology takes advantage of the ability of polymers like poly-N-
isopropylacrylamide (PNIPAAm) to shift between hydrophobic and hydrophilic status 
when the temperature ranges from 37ºC to 32ºC. Cell sheets can be serially stacked to obtain 
multilayered scaffoldless constructs (Figure 3). Such an approach has already been applied 
to obtain cell sheets composed of rodent [48, 49] and human [50] cells. Given the need for 
thick cardiac substitutes suited to comply with cardiac muscle continuous contractility, 
thermo-responsive technology has been envisaged as a possible answer to the lack of heart 
donors. Pre-clinical trials performed onto experimentally infarcted animals demonstrated 
that when a murine adipose-derived monolayer sheet is leant onto injured myocardium, it 
can be retained and help tissue repair [48]. Similarly, striking results are obtained when a 
Sca-1+ cardiac progenitor cell-derived sheet is used [49]. Finally, an interesting approach has 
been recently proposed to deliver cardiac stem cells cultured in the form of cardiospheres to 
the injured heart: cardiospheres were embedded into a cardiac stromal cell-derived sheet 
obtained by using poly-lysine/ collagen IV-coated dishes [51]. The formation of mature 
vessels as well as new cardiomyocytes in vivo was reported after 3 weeks.  
 
 
Fig. 3. Generation of scaffoldless multilayered bio-constructs by means of thermo-
responsive technology: cells grown in a monolayer onto thermo-responsive poly-N-
isopropilacrylamide (PNIPAAm)-coated dishes can be detached by lowering the 
temperature below 32°C. At 37°C the surface is highly hydrophobic and allows cell 
adhesion. When the temperature is lowered, PNIPAAm becomes hydrophilic, the cell sheet 
is detached and extracellular matrix (ECM) preserved. Multilayered cell sheets can be 
obtained by serially stacking monolayered sheets 
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4. Clinical trials  
In the attempt to transfer bench experience to bedside, a number of clinical trials in which 
different stem cell or progenitor subsets are used have been approved (see 
http://www.clinicaltrials.gov). Most of them are still in the recruitment phase while some 
already gave indications and preliminary results. Since most of the ongoing trials are based 
on the injection of raw stem cell preparations (mostly bone marrow-derived cells), the time 
and route of cell application remain the key problems to be addressed before proceeding to 
routine clinical practice. In this respect, recent animal experiments demonstrated that the 
acute phase of myocardial infarction is probably not suitable for stem cell engraftment and 
differentiation [52]. Therefore, the right moment in which stem cells should be delivered is 
to be studied. An overview on some of the ongoing clinical trials is given below. 
1. MAGIC (Myoblast Autologous Grafting in Ischemic Cardiomyopathy). In one of the 
first phase II clinical trials setup to study the possibility to use stem cells to treat cardiac 
pathologies, ninety-seven (97) patients undergoing coronary artery bypass grafting 
(CABG) were enrolled. 400-800 X 106 autologous myoblasts harvested from patient 
muscle biopsy were implanted in the akinetic area of ventricular wall 21 days after in 
vitro culture. The follow-up after 30 days and 6 months demonstrated the arising of 
arrhythmia events, thus requiring the implantation of pacemaker. Moreover, no cardiac 
function improvement was reported. Such negative results were ascribed to the 
inability of skeletal myoblasts to balance cell death and achieve complete 
electromechanical integration with the recipient myocardium. Finally, skeletal myoblast 
administration was reported to determine no enhancement in major cardiac adverse 
events and mild effects on left ventricular remodeling process [53, 54]. More recently, 
final results from SEISMIC [Safety and Effects of Implanted (Autologous) Skeletal 
Myoblasts (MyoCell) Using an Injection Catheter] Trial, a phase II-a study 
encompassing 40 patients experiencing congestive heart failure and receiving 
percutaneous intramyocardial injection of autologous skeletal myoblasts, reported the 
feasibility and safety of this procedure without significant arrhythmogenic events 
recorded at 6-month follow-up with respect to control groups, although left ventricular 
ejection fraction did not result significantly improve. These encouraging results suggest 
that myoblast cell therapy could be considered as a potential effective treatment when 
associated with standard medical therapy in patients with previously implanted cardiac 
defibrillators [55].   
2. TOPCARE-CHD, -AMI, -DCM (Transplantation of Progenitor Cells and 
Regeneration Enhancement in Acute Myocardial Infarction, Chronic Stable Ischemic 
Heart disease or Dilated Cardiomyopathy). In this complex clinical trial, a total of 346 
patients were classified to CHD, AMI or DCM pathologies and infused either with bone 
marrow cells (BMCs), blood-derived stem cells, or no infusion. In TOPCARE-CHD, 121 
patients (mean age: 59) with chronic stable ischemic heart disease (CHD) were treated. 
Although complications occurred in 21% of the patients during 3 months follow-up, 
BMC intracoronary administration was related with a reduction of both brain and atrial 
natriuretic peptide (NTP) serum levels (indicators of LV remodelling process) in the 
remaining population (79%), especially in patients with higher NTP levels at baseline 
and receiving a greater BMC number with a high functional capacity. Moreover, these 
results were also correlated with a left ventricular ejection fraction (LVEF) increase and 
better survival during the further follow-up, suggesting that cell therapy could be 
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associated with cardiac function enhancements in patients with advanced chronic post-
infarction heart failure [56]. Similarly, two hundred and four (204) patients were treated 
using bone-marrow-derived progenitor cells directly into the infarct artery three to 
seven days after an acute myocardial infarction (AMI). A statistically significant 2.5% 
improvement in left ventricular ejection fraction at four months was reported for 
patients randomized to the bone marrow injection [57]. Finally, intracoronary infusion 
of bone marrow cells was performed in 33 patients with dilated cardiomyopathy 
(DCM) by using an over-the-wire balloon catheter. Three month follow-up 
demonstrated an improvement in left ventricular pump function while a modest 
improvement in Brain Natriuretic Peptide (BNP) levels was reported after 1 year [6]. 
Importantly, the conditions chosen in the present clinical trial were representative of 
different conditions (acute, chronic phase) encountered in the clinic. Unfortunately, no 
clear indication on stem cell characterization or on their actual ability to regenerate 
contractile cells is available.  
3. TRACIA STUDY (Intracoronary Autologous Stem Cell Transplantation in ST 
Elevation Myocardial Infarction). The phase II/ III clinical trial aimed at evaluating the 
effects of intracoronary administration of adult stem cells on LV ejection fraction and 
major adverse cardiovascular events (MACE) after 6 months follow-up. For this reason, 
1-2 million CD34+ cells were injected through the infarct-related artery few days after 
post-infarct angioplasty using an "over-the-wire" catheter in 80 patients aging from 20 
to 75 years. The results of this study are still to be published. 
4. Combined CABG and Stem-Cell Transplantation for Heart Failure. Intramyocardial 
delivery of autologous bone marrow cells extracted from iliac crest and purified by 
Ficoll centrifugation, during cardiac surgery for CABG intervention in 30 patients, as 
compared to 30 patients undergoing CABG without cell infusion. Although information 
on the number and characteristics of cells to be injected has not been given, the trial is 
currently ongoing and the follow-up is scheduled in 6-12 months 
(http://clinicaltrials.gov).  
5. POSEIDON-Pilot Study (The Percutaneous Stem Cell Injection Delivery Effects on 
Neomyogenesis Pilot Study) Poseidon-pilot Study is a phase I/ II multi-center trial in 
which the trans-endocardial injection of autologous Mesenchymal Stem Cells (20-, 100-, 
200 X 106) is compared to autologous non-purified bone marrow cells and to allogeneic 
human Mesenchymal Stem Cells. The implant is performed during cardiac 
catheterization using the Biocardia Helical Infusion Catheter in fifty (50) patients 
suffering from chronic ischemic left ventricular dysfunction secondary to myocardial 
infarction. The data collection is currently ongoing. 
6. SCIPIO (Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy). 
This phase I clinical trial is aimed at assessing the safety and effectiveness of 
intracoronary autologous cardiac stem cell therapy. As such, forty (40) patients 
suffering from ischemic cardiomyopathy are exposed to intracoronary injection of 
cardiac resident stem cells (CSC). Cardiac stem cells are harvested from right atrial 
appendages and selected for c-kit expression, cultured and expanded in vitro prior to 
injecting them via intracoronary route, three to five months after CABG surgery. The 
hypothesis is that CSC infused into nonviable myocardial segments will regenerate 
infarcted myocardium by differentiating into cardiomyocytes and vascular cells. The 
preliminary results are encouraging: in the nine patients treated at four months after 
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CSC infusion, LVEF increased from 31.3 + 2.5 percent before CSC infusion to 38.8 + 3.2 
percent four months after CSC infusion. Moreover, in the five patients in whom data 
are available at 12 months after stem cell infusion, the improvement in LVEF observed 
at four months was even greater, averaging 15% at 12 months. The follow-up is 
scheduled in 1,5 years. 
7. ALCADIA (AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic 
cArdiomyopathy). In this phase I, multicenter clinical trial, a rather different approach 
is followed. In fact, patients’ own cardiac stem cells obtained by endo-myocardial 
biopsies are delivered by a single intramyocardial injection. The cells injected are 0.5 
million cells/kg (patient body weight) and their engraftment should be favored by the 
concomitant implantation of gelatin hydrogel sheet releasing human recombinant beta 
Fibroblast Growth Factor (bFGF), during CABG surgery. The study has been designed 
to treat refractory heart failure, ischemic cardiomyopathy or ventricular dysfunction 
cases. Importantly, this is the first clinical trial, to our knowledge, in which a human 
recombinant growth factor is used. Unfortunately, the number of enrolled patients is 
limited to six (6).  
8. REGEN-IHD (Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure). In 
this phase II/ III study, granulocyte-colony stimulating factor (G-CSF) is 
subcutaneously administered for 5 days to patients with heart failure secondary to 
ischemic heart disease to mobilize CD34+ bone marrow stem cells. A concomitant 
intracoronary  or intramyocardial administration of bone marrow derived stem cells is 
performed. The number of enrolled patients is high (165) and the aim of the study is to 
compare the effects of G-CSF and autologous bone marrow progenitor cell infusion on 
the quality of life and left ventricular function in the patients. The follow-up timepoint 
is scheduled in 6-12 months. 
A number of papers reporting statistical analyses and comparisons among the clinical trials 
in which stem and progenitor cells have been adopted are currently available. [For further 
information, please refer to www.clinicaltrials.gov].  
5. Conclusions 
The possibility to treat cardiac diseases by cell therapy techniques is an extraordinary 
promise. While a number of different approaches has been so far proposed to setup 
minimally invasive techniques for cardiac repair, few of them being already in the clinical 
experimental phase, basic questions still need to be addressed. In fact, the molecular 
processes leading to cardiac differentiation still need to be fully clarified, while the impact of 
novel, genetically modified cell types obtained from adult differentiated cells on cardiac 
microenvironment deserve further investigations. More importantly, the seek to identify 
suitable delivery systems (i.e. scaffolds) able to foster stem cell survival, growth and 
differentiation, while degrading without negative effects as the formation of new tissue 
occurs is still open. A look at the literature reveals that an impressive effort to translate the 
information obtained by in vitro and pre-clinical studies to the bedside is being produced. In 
particular, a number of stem cell subsets, which have been previously tested in vitro and in 
animal models, are currently being tested in phase I, II clinical trials. As expected, the 
predominant delivery system used in the ongoing clinical trials is intracoronary or 
intramural injection of stem cells. The possibility to adopt tissue engineering techniques to 
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design patient-specific cardiac substitutes containing synthetic or natural scaffolds is still far 
from being taken into consideration for clinical application, since any single formulation will 
have to be approved before clinical testing. 
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